A panel of independent experts has decided that alteplase, a clot-busting drug often used to treat strokes is safe and effective under current guidelines.
President of the Stroke Alliance for Europe (SAFE) awarded Professional Doctorate in Policy Research and Practice honoris causa from University of Bath
Published in the journal, Lancet Neurology, a new study suggests that understanding stroke severity, as well as time to treatment, is key to delivering effective and safe thrombolysis treatment.
The number of strokes across the UK is likely to rise by almost half (44%) in the next 20 years, according to a new report published today by the Stroke Alliance for Europe (SAFE) and the Stroke Association.
Published in the medical journal Stroke, a new US study suggests that treatment of chronic stroke patients with injections of modified, adult stem cells into their brains is safe, and could lead to recovery of movement that was originally lost due to stroke.
This research will investigate 2000 drugs that are already known to be safe for use in humans to see if they could help reduce the amount of damage to the brain an intracerebral haemorrhage (a type of stroke caused by a bleed in the brain) causes.
This study will investigate whether early initiation of direct anticoagulant drugs will be as safe as later initiation in stroke patients with an abnormal heart rhythm (atrial fibrillation). It will also investigate whether early initation could lead to fewer recurrent strokes.
Professor Joanna Wardlaw CBE talks about the new SVDs@target programme - Targeting interventions for small vessel disease to prevent stroke and dementia. This programme was funded by a 6 million euro grant from the European Union’s Horizon 2020 programme.
Funded by the European Union (EU), a new international study called PROOF will investigate whether high-dose oxygen therapy can reduce the effects of stroke.
The Stroke Association is a member of the Stroke Alliance For Europe (SAFE), which will work on communication of information about the PROOF trial to non-clinical audiences.
This study will show whether more intensive lowering of blood pressure (BP) in survivors of intracerebral haemorrhage (ICH) is feasible, safe and effective in reducing brain injury. If successful, the study will pave the way for the design a larger definitive trial.